Richter transformation (RT) represents an uncommon (2% to 10%) but feared complication
of chronic lymphocytic leukemia (CLL). The disease is characterized by rapid disease …

Patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (NHL) after
anti-CD19 chimeric antigen receptor T-cell therapy (CART19) have poor prognosis with a …

Diffuse large B cell lymphoma (DLBCL) has a variable course of disease among patients as
it consists of subgroups that are clinically, biologically and molecularly heterogeneous. In …

Underrepresentation of racial and ethnic subgroups in cancer clinical trials remains a
persistent challenge. Restrictive clinical trial eligibility criteria have been shown to …

Diversity, equity, and inclusion (DEI) in research is important. This is the case not only
because it is simply the right thing to do but also because DEI fosters collaboration …

Underrepresentation of racial and ethnic subgroups in cancer clinical trials remains a
persistent challenge. Restrictive clinical trial eligibility criteria have been shown to …

Up to 50% of diffuse large B-cell lymphoma (DLBCL) patients are ineligible for participation
in clinical trials. Ineligible patients have inferior outcomes, but less is known about the …

Real-world data (RWD) are essential to complement clinical trial (CT) data, but major
challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in …

Prior studies have demonstrated that certain populations including older patients,
racial/ethnic minority groups, and women are underrepresented in clinical trials. We …

Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell
lymphoma (DLBCL) have shown negative results, which may be due in part to onerous …